Page last updated: 2024-12-06

phenylethylmalonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylethylmalonamide: A metabolite of primidone. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23611
CHEMBL ID249467
CHEBI ID8097
SCHEMBL ID341785
MeSH IDM0016562

Synonyms (41)

Synonym
malonamide, 2-ethyl-2-phenyl-
propanediamide, 2-ethyl-2-phenyl-
brn 1966103
pema (amide)
2-ethyl-2-phenylpropanediamide
phenylethylmalondiamide
einecs 230-583-9
OPREA1_383473
pema
phenylethylmalonamide
2-phenyl-2-ethylmalondiamide
7206-76-0
C07499
ccris 4700
2-ethyl-2-phenylmalonamide
80147-40-6
CHEMBL249467
chebi:8097 ,
FT-0668362
inchi=1/c11h14n2o2/c1-2-11(9(12)14,10(13)15)8-6-4-3-5-7-8/h3-7h,2h2,1h3,(h2,12,14)(h2,13,15)
jfzhpfoxaaiumb-uhfffaoysa-
A837408
2-ethyl-2-phenyl-propanediamide
2-phenyl-2-ethylmalonamide
67cfd7341w ,
unii-67cfd7341w
4-09-00-03386 (beilstein handbook reference)
2-ethyl-2-phenylmalondiamide
propanediamide,2-ethyl-2-phenyl-
phenyl-2-ethylmalondiamide, 2-
primidone impurity a [ep impurity]
SCHEMBL341785
phenyl-ethylmalonamide
AKOS024284175
2-ethyl-2-phenylmalonic diamide
ethylphenylmalondiamide
W-104501
STL415949
DTXSID3025885
Q3742460
primidone impurity a

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" PRM is a relatively nontoxic anticonvulsant with a different action than PB, and PEMA is both a weak and a relatively toxic anticonvulsant."( Primidone, phenobarbital, and PEMA: I. Seizure protection, neurotoxicity, and therapeutic index of individual compounds in mice.
Bourgeois, BF; Dodson, WE; Ferrendelli, JA, 1983
)
0.27

Pharmacokinetics

The study looked at the differences of primidone metabolism among humans, rats, and mice. The peak concentration occurred later for phenylethylmalonamide and phenobarbital.

ExcerptReferenceRelevance
" The half-life of PB is twice that of PRM and PEMA."( Single-dose pharmacokinetics and anticonvulsant efficacy of primidone in mice.
Friel, PN; Leal, KW; Rapport, RL; Wilensky, AJ, 1979
)
0.26
" Peak PEMA serum levels were obtained within 4 h of intake, half-life values ranged from 30."( Pharmacokinetics of phenylethylmalonamide (PEMA) in elderly men.
Berry, DJ; Crome, P; Newberry, JE; Streete, JM, 1987
)
0.6
" The pharmacokinetic parameters, calculated according to a 1-compartment open model, showed the following values (mean +/- SD): terminal half-life, 15."( Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration.
Pisani, F; Richens, A,
)
0.45
" Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients."( Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs.
Berry, DJ; Cottrell, PR; Perucca, E; Pisani, F; Richens, A; Schäfer, H; Streete, JM, 1982
)
0.59
"Physiologically based pharmacokinetic modeling of the parent chemical primidone and its two metabolites phenobarbital and phenylethylmalonamide (PEMA) was applied to investigate the differences of primidone metabolism among humans, rats, and mice."( Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice.
El-Masri, HA; Portier, CJ, 1998
)
0.73
" This was also the case for phenylethylmalonamide and phenobarbital but peak concentration occurred later."( Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat.
Nagaki, S; Patsalos, PN; Ratnaraj, N,
)
0.63

Bioavailability

ExcerptReferenceRelevance
"5 to 4 hours and the oral bioavailability was 86."( Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration.
Pisani, F; Richens, A,
)
0.45
" The oral bioavailability estimated on the basis of the recovery of unchanged drug in the urine of normal subjects was at least 80%."( Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs.
Berry, DJ; Cottrell, PR; Perucca, E; Pisani, F; Richens, A; Schäfer, H; Streete, JM, 1982
)
0.59
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Maintenance period blood samples were taken from fasted dogs 7 hours after dosing in the 3rd, 5th, 7th, and 9th months of the trial to determine therapeutic serum concentrations of primidone and its metabolites."( Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide in epileptic dogs.
Cunningham, JG; Haidukewych, D; Jensen, HA, 1983
)
0.49
" Serum primidone concentrations decreased after repeated dosing and were measurable in only 1 dog 24 hours after the 21st dose and peak concentrations of 4 to 7 micrograms/ml were measured at 4 hours after the 22nd dose."( Serum concentrations of primidone and its metabolites, phenylethylmalonamide and phenobarbital, in the dog.
Yeary, RA, 1980
)
0.51
"We describe a procedure for determining 2-ethyl-2-phenylmalonamide (I) in serum of epilepsy patients dosed with primidone (II) for seizure control, by extracting the sample with chloroform under basic conditions, with use of an internal standard, 2-ethyl-2-(p-tolyl)malonamide, and without derivative formation."( Monitoring 2-ethyl-2-phenylmalonamide in serum by gas-liquid chromatography: application to retrospective study in epilepsy patients dosed with primidone.
Haidukewych, D; Rodin, EA, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amineA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (81.97)18.7374
1990's6 (9.84)18.2507
2000's4 (6.56)29.6817
2010's1 (1.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.41 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.00 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.03%)5.53%
Reviews0 (0.00%)6.00%
Case Studies7 (10.61%)4.05%
Observational0 (0.00%)0.25%
Other57 (86.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]